TriangleAzacitidine (NCT03383575)
Azacitidine trial for Acute Myeloid Leukemia (NCT03383575). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 12 or older with IDH2-mutated MDS, CMML, or specified AML with 20–30% marrow blasts.
The idea: daily oral enasidenib blocks mutant IDH2 to help abnormal cells mature. Selected higher-risk patients without prior hypomethylating therapy also receive azacitidine by vein or under the skin, days 1–7 of 28-day cycles. Patients whose disease relapsed or resisted hypomethylating therapy receive enasidenib alone.
This phase 2 study plans 63 patients. Courtney DiNardo leads at MD Anderson in Houston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.